Mankind Pharma Acquires Rivotril Brand from Roche to Boost CNS Portfolio in India

Rivotril, an innovator/reference brand of clonazepam, is widely prescribed for the management of neurological and psychiatric conditions. The brand is regarded as a “textbook” product with a strong clinical legacy and high recall among specialists. The acquisition is expected to strengthen Mankind Pharma’s presence in the central nervous system (CNS) therapy segment and complement its existing neuro portfolio.

The company stated that the move aligns with its strategic focus on expanding its chronic therapy business, which has been witnessing steady growth through new launches, in-licensing partnerships and portfolio additions. Chronic therapies are increasingly contributing to the company’s overall business, with a focus on deepening engagement with specialists and key opinion leaders.

Commenting on the development, Atish Majumdar, Senior President – Sales & Marketing, Specialty Business, said that the acquisition supports the company’s strategy of strengthening its position in chronic and specialty therapies. He added that the company sees opportunities to further expand the platform through potential line extensions to address evolving patient and physician needs in the CNS segment.

Mankind Pharma plans to leverage its extensive field force and nationwide distribution network to enhance access to Rivotril across healthcare institutions and prescribers. The company currently engages with over five lakh doctors and has built a strong prescription base across urban and semi-urban markets.

Mankind Pharma is one of India’s pharmaceutical companies with a strong domestic presence across both acute and chronic therapeutic areas. The company operates across segments including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynecology and respiratory, along with a significant consumer healthcare portfolio.